Sushil Rijhwani

Sushil Rijhwani has diverse work experience in the pharmaceutical industry, with a focus on project planning, management, and decision analysis. Sushil started their career at Massachusetts Institute of Technology as a Post-Doctoral Research Associate. Sushil then joined Bristol-Myers Squibb, where they held various roles including Manager of Operations & Planning, Associate Director of CMC Project Planning and Management, and Director of Portfolio & Asset Strategy/Oncology. At Bristol-Myers Squibb, they managed teams, led decision analysis processes, conducted forecasting and risk assessments, and played a key role in strategic planning for oncology compounds. Sushil also worked at Daiichi Sankyo, Inc. as a Senior Director of Project & Portfolio Management, where they focused on portfolio prioritization, resource management, and project coordination. Currently, they are working at Taiho Oncology, Inc. as the Sr. Vice President of Clinical & Pharmaceutical Development Management, responsible for managing project planning and management, clinical budget management, and pharmaceutical development and clinical supply operations. Throughout their career, they have demonstrated expertise in coordinating cross-functional teams, facilitating decision-making processes, and optimizing R&D budgets.

Sushil Rijhwani has an extensive education history. Sushil earned a high school diploma from Montfort School in 1988. Sushil then went on to attend the Indian Institute of Technology, Delhi, where they obtained a B.Tech. degree in Chemical Engineering in 1992. Following this, Sushil pursued further studies at Rice University, completing their Ph.D. in Chemical Engineering between 1992 and 1997. In 2001, they enrolled at Lehigh University and obtained an MBA with a focus on Marketing/Supply Chain Management, which they completed in 2004. Sushil continued to enhance their educational background by earning two certificate programs from Stanford University. One focused on Advanced Project Management, which they finished in 2013, and the other concentrated on Strategic Decision and Risk Management, which was completed in 2012.